Starches Digestion After Obesity Surgery.
GLUBYPASS
2 other identifiers
interventional
13
1 country
1
Brief Summary
Despite an impressive capacity to induce diabetes remissions, the gastric bypass surgery has been associated with the onset of hyperglycemic peaks, which are very intensive and transient, in formally non diabetic patients. The aim of this study is to study the digestion of starch as compared to that of glucose (same glucose load) before and after gastric bypass surgery in obese patients. Volunteers will be recruited among the candidates to a gastric bypass, and will be studied before and 3 months after surgery. They will have on each occasion 2 random meals, corresponding to 30g glucose, one made of starch the other made of glucose, both naturally labeled with 13C. The digestion of starch will be assessed with the increase in the plasma 13C-glucose tracer. Plasma samples will be collected for 3 hours. Some studies have already investigated time of absorption of glucose, but any study has examined the time of digestion of glucose. Other study always used glucose syrup, so they cannot have results about digestion. It is the reason why, in this study, glucose syrup and a starch meal will be taken by the same patient and glycaemia will be compared. In this way, results will be obtained about the kinetic of digestion of starch.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable obesity
Started Feb 2018
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 24, 2016
CompletedFirst Posted
Study publicly available on registry
June 3, 2016
CompletedStudy Start
First participant enrolled
February 19, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 2, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
July 2, 2019
CompletedNovember 4, 2021
October 1, 2021
1.4 years
March 24, 2016
October 27, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change in C13 glucose marker appearance: starch diet.
Appearance of the C13-glucose tracer in the plasma, since the beginning of the diet with the starch diet.
Change from baseline C13 glucose marker appearance at 3 months after surgery
Secondary Outcomes (2)
C13 glucose marker appearance: glucose diet.
Change from baseline C13 glucose marker appearance at 3 months after surgery
Insulin secretion
Change from baseline insulin secretion at 3 months after surgery
Study Arms (2)
Meal with glucose syrup
EXPERIMENTALMeal with glucose syrup : 30g of glucose mixed with 150 mL of water and dived into three 50 mL portions. It will be consumed in 15 minutes
Starch meal
EXPERIMENTALStarch meal with 30g mixed in 120 mL of water. It will be consumed in 15 minutes and it represents 30g of glucose
Interventions
Before bypass surgery, patients will take randomized meal. One day a starch meal and another day a glucose syrup meal. 3 months after surgery, they will take these 2 randomized meal again, one day the first one, and the day after the other one.
Before bypass surgery, patients will take randomized meal. One day a meal with glucose syrup and another day a starch meal. 3 months after surgery, they will take these 2 randomized meal again, one day the first one, and the day after the other one.
Eligibility Criteria
You may qualify if:
- Obese patients before obesity-surgery (HAS 2009 criteria for obesity-surgery)
- Patients accepted for a gastric bypass
- Patient consent the principle of 2 evaluations (one before surgery and another 3 months after surgery)
- Patient that give their informed consent before any procedure for the study
- Patient affiliated with a health insurance scheme
You may not qualify if:
- Diabetes (whatever the treatment), post-surgery diarrhea, small intestine disease
- Known microbial outbreak
- Anti-thrombin therapy
- Treatment which can modify the intestinal transit (anti-diarrhea, thyroid hormones…)
- Pregnant woman or breastfeeding.
- Patient not available for the two evaluations
- Protected adults (guardianship by court order)
- Patients participating to another treatment research protocol during the time of this study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Department of Endocrinology, metabolic diseases and nutrition
Toulouse, 31059, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Patrick RITZ, MD
University Hospital, Toulouse
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- BASIC SCIENCE
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 24, 2016
First Posted
June 3, 2016
Study Start
February 19, 2018
Primary Completion
July 2, 2019
Study Completion
July 2, 2019
Last Updated
November 4, 2021
Record last verified: 2021-10
Data Sharing
- IPD Sharing
- Will not share